GlassScriptPhysician profile
Ravikumar Kanneganti
NPI 1679643191
$13,228.57
in general payments reported to CMS, 2019-2025
32 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $1,941 · 2021: $2,047 · 2022: $2,006 · 2023: $2,517 · 2024: $1,560 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,763 · Education: $85.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,763.32 |
| Education | $85.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,532.03 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,404.86 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,341.21 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $1,295.60 | 2019-2022 | |
| Tris Pharma INC | $1,092.87 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $975.68 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $892.72 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $618.33 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $593.19 | 2021-2025 | Qelbree, Qelbree |
| Indivior INC. | $465.87 | 2021-2024 | Perseris |
| Lundbeck LLC | $417.36 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $414.82 | 2019-2021 | |
| Corium, LLC | $335.05 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $249.18 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $221.31 | 2024-2025 | Cobenfy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $198.60 | 2022-2025 | Auvelity |
| Shire North American Group INC | $139.93 | 2019 | |
| Alkermes, INC. | $135.21 | 2019-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $128.91 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $109.82 | 2019-2021 | |
| Neuronetics, INC. | $106.65 | 2019-2024 | Neurostar Tms Therapy System |
| Merck Sharp & Dohme LLC | $100.20 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $98.45 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $84.35 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $63.58 | 2019-2020 | |
| Allergan, INC. | $62.43 | 2020 | |
| Collegium Pharmaceutical, INC. | $59.59 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.71 | 2025 | |
| Jazz Pharmaceuticals INC. | $20.12 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.73 | 2020 | |
| Biogen, INC. | $17.92 | 2024 | |
| Avanir Pharmaceuticals, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravikumar Kanneganti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.